Designer immune cells take on rare sarcomas in early trial
NCT ID NCT06083883
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 43 times
Summary
This early-phase trial tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with standard chemotherapy, is safe for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. The NK cells are designed to recognize and attack cancer cells that carry a protein called NY-ESO-1. The study will enroll 44 participants to find the best dose and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered natural killer (NK) cells that target NY-ESO-1, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If it works, this could point toward a new treatment option for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not responded to other therapies.
What could go wrong
This is a very early Phase I trial with only 44 participants, so the main goal is safety, not proof of effectiveness. The therapy may cause serious side effects from the chemotherapy or the NK cells, and it may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.